Our latest wrapup of headlines from other publications that impact the Triangle tech community includes: Paul Gilster’s column on talking to Siri, Cortana and more; Icagen boosts its drug discovery resources; The N&O profiles the head of the Institute for Emerging Issues; and a look at key points from the proposed Bioventus IPO.
The details:
- The N&O: When you talk to Siri, Cortana and Google Now, who’s listening?
Technology columnist Paul Gilster writes about all those “voice” assistants:
“I’m starting to enjoy talking to computers. I don’t use speech-to-text all that much because I’m so keyboard-oriented, but I love being able to run a search by voice or ask for last night’s baseball scores. Siri works well for this, though I’m now using Android and am thus in the hands of Google Now, which keeps asking me to re-train it by speaking ‘OK Google’ over and over again. Despite this annoyance, a day rarely passes that I don’t talk to Google Now.”
Read the details at:
Read more here: http://www.newsobserver.com/news/business/biz-columns-blogs/article87059847.html#storylink=cpy
- xConomy: “Icagen Boosts Drug Discovery Capabilities With Sanofi Site Purchase”
xConomy’s Frank Vinluan takes a look at a recent deal made by Durham-based Icagen:
“Icagen is expanding its capabilities to search for new drugs by bolting on a Sanofi research site in Arizona and gaining access to the lab’s library of compounds.”
Read the details at:
Icagen Boosts Drug Discovery Capabilities With Sanofi Site Purchase
- N&O: Tar Heel (of the week): Anita Brown-Graham facilitates a meeting of the minds to make NC a better place
The N&O offers a profile of Anita Brown-Graham, the head of the Institute for Emerging Issues:
“I always liked the most difficult clients,” Brown-Graham says. “I like people who say what they’re thinking even if they may make other people uncomfortable, and I’m fascinated by people who have different perspectives than mine.”
Read more at:
http://www.newsobserver.com/news/business/article87364257.html#storylink=cpy
- MedCities: 5 takeaways from Bioventus IPO move
News service MedCities takes a look at the Bioventus IPO offering:
“The medical technology company Bioventus jumped deeper into biotech’s tumultuous waters [last week] by registering a $150 million initial public stock offering.”
Read more at:
